Precision Immunotherapy for Sepsis: ImmunoSep Trial Shows Early Organ‑Function Benefit with Targeted Anakinra or IFN‑γ
Posted inCritical Care Infectious Diseases news

Precision Immunotherapy for Sepsis: ImmunoSep Trial Shows Early Organ‑Function Benefit with Targeted Anakinra or IFN‑γ

The ImmunoSep randomized trial found that biomarker-guided immunotherapy (anakinra for macrophage activation‑like syndrome; interferon‑γ for sepsis‑induced immunoparalysis) improved organ dysfunction by day 9 versus placebo, though 28‑day mortality was unchanged. Safety signals require follow‑up.
Endothelial Glycocalyx Degradation in Sepsis: Insights from the CLOVERS Trial on Fluid Resuscitation Strategies and Mortality
Posted inClinical Updates Critical Care news

Endothelial Glycocalyx Degradation in Sepsis: Insights from the CLOVERS Trial on Fluid Resuscitation Strategies and Mortality

This article reviews findings from the CLOVERS trial analyzing endothelial glycocalyx degradation in sepsis, demonstrating its strong association with mortality but showing no impact of liberal versus restrictive fluid resuscitation strategies on glycocalyx integrity or survival outcomes.